HPV diseases and cervical cancer: Summing Up

Thursday 12 April 2018

Morning


8.00 Opening Lecture


8.20 Welcome P. Davies.-A. Frega - C. Gentili


ROOM A (Plenary session)

8.30 Opening Lecture
Chairman: G. Scambia | Speaker: W. Ricciardi
- HPV infection and carcinogenesis: a public health perspective.


8.50-10.20 HPV infection and Carcinogenesis
Chairpersons: P. Davies - A. Venuti | Speakers: J. Doorbar , B. Moscicki
- Human papillomavirus infection and the induction of neoplasia.
- The natural history of HPV infection in screening age women; do we have enough
data to really understand what is happening in this age group?
- Persistent vs repeated infections; can we tell the difference and does it make a
difference to cervical carcinogenesis?
- HPV infection in men; do we understand the natural history and clinical
implications for men and their partners?


10.20-11.00 Epidemiology of Cervical Cancer and HPV Infection
Chairpersons: A. Castanon – A.Lukic | Speakers: P. Davies, J. Dillner
- Cervical cancer trends around the world; are we making a difference?
- HPV vaccination and its impact on HPV infection rates around the world.


11.30-13.00 Cervical Screening
Chairpersons: J. Dillner- C. Gentili | Speakers: A. Castanon, P. Davies, M. Goodman
- The current status of cervical screening programmes around the world; are we
making progress where it is needed most or just improving the best?
- HPV testing for primary screening; who is doing what?
- The latest data from the HPV primary screening programmes; the benefits and the
challenges that remain to be solved.
- Cervical screening: is there still a role for the Pap test?


ROOM B

9.00-13.00 Free Communications
Chairpersons D. French - E. Giarnieri. - R.Senatori

Afternoon


ROOM A


14.30-15.40 Cervical Screening: the New Challenges
Chairpersons: A. Frega - U. Petry | Speakers: A. Castanon, M. Goodman, W. Huh
- Estimating the impact of HPV primary screening and HPV vaccination on cervical
cancer rates.
- The evolution of HPV testing in the USA.
- HPV screening recall and follow-up recommendations; do doctors stick to the rules?


15.40-16.50 HPV Positive, what Next?
Chairpersons: M. Cruickshan - M. Peroni | Speakers: P. Martin Hirsch, K.U. Petry
- HPV positive; what are the triage options and their associated risks.
- How does HPV status affect the treatment of low-grade cervical disease?
- Persistent HPV infection without colposcopically visible cervical disease: how
common and what is it the appropriate follow-up?


17.10-18.00 Colposcopy in the Era of HPV Vaccination and HPV Screening
Chairpersons: W. Huh - F. Sopracordevole | Speakers: M. Cruickshank, P. Martin Hirsch, K.U. Petry,
- The implications of HPV vaccination for the practice of colposcopy.
- HPV primary screening; will this affect the accuracy of colposcopy?
- Should colposcopists be re-trained to deal with the realities of the HPV era?


18.00-18.55 Noncompliance with Referral to Colposcopy
Chairpersons: P. Martin Hirsch - C. Zanardi | Speakers: M. Cruickshank, U. Tabuica, J. Waller
- Non compliance with colposcopy referral; the extent of the problem in different countries.
- Why do women decide not to go to colposcopy?
- Understanding and reducing the adverse psychological impact of colposcopy


ROOM B


14.30-16.00 Updates in Molecular Biology
Chairpersons: D. French - A. Venuti | Speakers: L. Dillner, J. Doorbar, B. Moscicki
- Latent papillomavirus infections: the role of the HPV test.
- Getting around in the molecular testing jungle: what clinicians and pathologists
should know to properly interpret the results.
- Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by
combining the novel molecular biomarker PanHPVE4 with P16INK4a.
- The role of cytology and HPV genotyping in screening for anal cancer.


16.00-16.50 Updates in Cytopathology
Chairpersons: M. Benevolo – E. Giardini | Speakers: M.R. Giovagnoli, G. Negri
- Is the new Bethesda system tailored for HPV screening and molecular diagnosis?
- Cytology triage: what molecular testing cannot provide.


17.10-18.45 Ask the Experts
Coordinators : P. Davies- A. Frega- C. Gentili | Experts: J. Dillner, J.Doorbar, M. Goodman,
B. Moscicki, W. Prendiville, G. Negri
- Open forum: What would you like to ask a panel of experts?

 

Friday 13 April 2018


Morning


ROOM A (Plenary session)


8.30-10.30 Vaccination
Chairpersons: M. Cruickshank - A. Lukic | Speakers: R. De Vincenzo, J. Dillner,
L. Mariani, M. O'Connor, J. Waller
- HPV vaccination around the world today: the programs and the coverage rates.
- HPV vaccination; long-term efficacy and protection. What are the data?
- Screening in vaccinated and unvaccinated women: are two algorithms necessary
and if so how do we implement them?
- HPV vaccination of boys; who is doing what?
- Improving HPV vaccination coverage; what works and what doesn’t.
- The nonavalent HPV vaccine: what changes?


11.10-13.00 Ensuring the Safety and Effectiveness of Colposcopy

Chairpersons: A.Ciavattini - M. O'Connor | Speakers: M. Cruickshank, W. Huh,
P. Martin Hirsch, K.U. Petry, W Prendiville
- Treatment of cervical pre-cancer, current best practice
- Colposcopy training; the similarities and differences across Europe.
- Training colleagues in middle income countries
- Quality assurance of colposcopy; the European perspective
- Quality assurance of colposcopy; the American perspective.


ROOM B


8.30-11.00 Free Communications

Chairpersons: A. Biamonti- R. Barbero – E.Carico

HPV INFECTION AND CANCEROGENESIS

8.30 – 8.37
Case-control study on the efficacy of carboxymethylbetaglucan-lactoferrin association in women with high-risk Human Papillomavirus (HPV) uterine cervical infection
A.A. Criscuolo, E. Guri, M. Ciotti, F. Sesti, E. Piccione

CERVICAL SCREENING

8.37 – 8.44
Reducing unnecessary colposcopy by risk discrimination. HPV genotyping with NILM or low-grade cytology in screening paradigms: systematic review
J. Andrews

8.44-8.58
Risk of invasive lesions in cytologically atypical glandular cells (AGC) on conventional Pap Test: follow up study
E. Isidoro

8.51-8.58
Primary cervical cancer screening with a 5-type HPV e6/e7 mRNA test: results of 10 years follow-up
S.W. Sørbye , A.Rad , F.E. Skjeldestad

8.58-9.05
HPV test in triage of ASC-US/LSIL - the risk of CIN3+ in 5-type HPV E6/E7 mRNA negative women
S.W. Sørbye, M.M. Slettebak, F.E. Skjeldestad

9.05-9.12
Cytology and 3-type HPV e6/e7 mRNA co-testing in women 25-33 years
S.W . Sørbye, F.E. . Skjeldestad FE


9.12-9.19
Detection of CIN2+ in women with normal cytology - the added value of a 3-type HPV E6/E7 mRNA test
S.W. Sørbye, B. Westre, A. Giske, H. Guttormsen, F.E. Skjeldestad

COLPOSCOPY

9.29-9.36
Smartscopy: the speculoscopy applied to the smartphone can be an efficient alternative to the traditional one?
C. Bondi, A. Palmeri, M. Maramai, F. Casabona

9.36-9.43
Endocervicoscopy: a new imaging technique and its accuracy in studing cervical intrapithelial lesion
N. De Rosa, G. Lavitola, M.Palma, R.Gallo, M.C Pagliuca, C. Di Filippo, G. Bifulco

9.43-9.50
How to use a low cost CCD camera for hysteroscopy and colposcopy: our “all-in-one” device
M. Maramai, C. Bondi, A. Palmeri, F. Casabona

9.50-9.57
LSIL: colposcopic pictures and indication to direct biopsy. A study of the SICPCV
M.Serri, F. Sopracordevole, P.Garutti, M. Fallani, B. Gardella, P.Scirpa, M.T. Schettino, A. Del Fabro, A. Pieralli, F. Ravennati, S.Montori, R.Agrusti, M.Papiccio, A.C.Boschi, M.R. Primieri, F. Cigolot, A. Ciavattini

9.57-10.04
Evidence for clinical utility of extended HPV genotyping in persistence tracking and follow-up after abnormal results and colposcopy
J. Andrews

MISCELLANY

10.14-10.21
Lymphoma of the lower female genital tract
R. Sparic, A. Dobrosavljevic, J. Stulic, L. Nejkovic

10.21-10.28
Tubulosquamos polyp in vagina together with VAIN II/III
R. Sparić, J.Stulic, A. Dobrosavljevic, L. Nejkovic


11.10-13.30 Free Communications

Chairpersons: D. French - E. Giarnieri - R. Senatori

EPIDEMIOLOGY OF CERVICAL CANCER AND HPV INFECTION

11.10-11.17
The risk of cervical atypia in oral contraceptive users
I. Adhikari, T.Eriksson, T. Luostarinen, M.Lehtinen, D.Apter

11.17-11.24
Countries of Eastern Europe and Central Asia: the situation of HPV infection in HIV-positive women
A.A. Popova, O.Y. Shipulina, M.O. Deulina

11.24-11.31
Prevalence of cervical HPV lesions in patients with bowel inflammatory diseases in immunosuppressive treatment and cervical screening: multidisciplinary management experience in a referral center
C.Ricci, F.Scaldaferri, F. Colombo, A. Gasbarrini, G. Scambia, R. De Vincenzo

11.31-11.38
Role of vaginal TIAB in cervical reepithelialisation and highrisk HPV clearance in patients with low-grade cervical lesions
C.Ricci, M.T.Evangelista, G. Scambia, R. De Vincenzo

11.38-11.45
HPV-HR prevalence and type distribution in women with NILM or HSIL Pap smear in Russia.
O.Y. Shipulina, M.Y. Dmitryukova, G.V.Leshkina

MOLECULAR BIOLOGY AND CYTOPATHOLOGY

11.55-12.02
The risk of developing a CIN2+ lesion in women with HPV16 and 18, versus women with other HPV types: follow-up study
E. Isidoro, U. Wiesenfeld, M. Di Napoli, A. Romano, J. Dobric, C. Biagi, F. Variola, S.Tomasi, D.Santon, S.Dudine, F. Giudici, L. Di Bonito, F. Zanconati

12.02-12.09
Mesenchymal stem cells from cervix: what is about age and inflammation?
G. Delli Carpini, M. Orciani, M. Caffarini, R. Lazzarini, S. Guizzardi, D. Tsiroglou, R. Di Primo, A. Ciavattini

12.09-12.16
Molecular study of HPV-related oropharyngeal carcinoma
G. Ferrario, P. Morbini, P. Alberizzi, M. Benazzo

12.16-12-23
HR-HPV negative cases of cytological HSIL and additional testing results for low and unknown risk types.
G.V. Leshkina, O.Y. Shipulina, T.N. Romanyuk

12.23-12.30
DNA HPV testing and diagnostic cytopathology for oral cancer screening
Navone R., Amodeo E., Lapucci C., Crò F., Pentenero M., Gandolfo S.

12.30-12.37
Expression of E6/E7 HPV-DNA, HPV-mRNA and colposcopic features in management of CIN2/3 during pregnancy
C. Leone, D. French, M. Pavone, A. Frega, D. Caserta

TREATMENT AND FOLLOW-UP

12.47-12.54
Evidence for clinical utility of extended HPV genotyping in Test of Cure after treatment of CIN2+
J. Andrews

12.54-13.01
Radiofrequency and poration for the treatment of HPV genital warts: a case report
C. Catalisano

13.01-13.08
Role of “close” negative endocervical margin in treatment failure after cervical excision for cervical intraepithelial neoplasia: a retrospective study
G. Delli Carpini, A. Del Fabro, L. Alessandrini, M. Buttignol, V. Canzonieri, A. Cagnacci, F. Sopracordevole, A. Ciavattini

13.08-13.15
LLETZ in woman of reproductive age diagnosed with squamous intraepithelial lesions: the problem of specimen artifacts
R.Sparic, S.Kadija, R. Stefanovic, L.Jovanovic, T. Janjic, J.Bila, M. Berisavac


Afternoon


ROOM A


14.30-15.30 Public Education and Coverage Rates
Chairpersons: F.Boselli - W.Prendiville | Speakers: M. Cruickshank, L. Dillner, M. O'Connor, J. Waller
- Social and psychological impact of HPV testing in cervical screening.
- Reaching under- or never-screened women; is self-sampling the answer?
- The impact of HPV vaccination on cervical cancer screening coverage; are the
predictions proving to be true?
- HPV vaccination for adolescents, Pap screening for under-30s, HPV screening for
over 30’s; how can we effectively communicate all this to ensure high programme
participation?


15.30 - 16.15 HPV and Vaginal Infection
Chairpersons: A. Biamonti - U. Tabuica | Speakers: F. De Seta, B. Moscicki
- The role of vaginal microbiome in HPV infection and disease.
- Chlamydia trachomatis infection: epidemiology, treatment and its role in HPV disease
- The effect of intrauterine devices on acquisition and clearance of human papillomavirus


16.15-16.55 Miscellanea
Chairpersons: R. Senatori- F. De Seta | Speakers : D. Caserta,W. Prendiville, U. Tabuica, F. Torcia
- HPV and fertility.
- Potential innovations in cervical precancer management
- The role of oral contraception and hormone replacement therapy in HPV infection
and disease.
- The ultrasound in the evaluation of preneoplastic and neoplastic lesions of the uterine cervix


ROOM B


14. 30 -15.20 Pap Smear: Never Say Never Again

Chairpersons: M. Benevolo – E. Carico | Speakers: W. Huh, G. Negri
- Don’t forget me: cytology of HPV negative lesions.
- What clinicians need from cytology.

15.20-17.20 The Cervical Cytopathology in the HPV Testing Era
Coordinators: M.R. Giovagnoli - G. Negri
- An interactive seminar slide of cervical cytopathology.


ROOM A (Plenary session)


Chairpersons: A. Frega – C. Gentili
17.20 Presentation of the Best 3 Free Communications and Award for the Best
17.50 General Discussion
18. 00 ECM Test
18.20 Prize giving for the three best speakers and conclusions

 

 

Download the Program

Contact Us

Please fill in the form below to contact the Organizing Secretariat.